What are Viridian Therapeutics, Inc.'s profit margins?

Viridian Therapeutics, Inc. (VRDN) runs a 36.3% gross margin and a -543.9% operating margin, with a -508.5% net margin.

Where do Viridian Therapeutics, Inc.'s ratios come from?

Every ratio is computed from Viridian Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Viridian Therapeutics, Inc. VRDN Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Operating margin	-543.9%+111,047pp	-512.9%+98,506pp	-463.5%+93,259pp	-121,831.1%-34,753pp	-111,591.1%-28,996pp
Net margin	-508.5%+101,584pp	-483.6%+88,904pp	-426.6%+84,701pp	-112,806.9%-33,621pp	-102,092.4%-26,355pp
EBITDA margin	-543.2%+110,878pp	-512.3%+98,327pp	-462.9%+93,072pp	-121,672.8%-34,793pp	-111,421.5%-29,022pp
Free cash flow margin	-428.4%+92,401pp	-390.8%+76,705pp	-461%+64,914pp	-101,507.9%-42,890pp	-92,829.8%-34,426pp
Returns
Return on equity	-58.1%-6.2pp	-49.2%-0.7pp	-49.9%+2.0pp	-65.9%-11.9pp	-51.9%-5.2pp
Return on assets	-49.7%-2.0pp	-41.7%+2.1pp	-44.8%+1.9pp	-58.9%-10.2pp	-47.8%-4.9pp
Return on invested capital	-76.5%-10.7pp	-64.8%-0.9pp	-73.9%+4.2pp	-85.9%-12.1pp	-65.8%-4.9pp
Efficiency
Asset turnover	0.1×+0.1×	0.1×+0.1×	0.1×+0.1×	0×0.0×	0×0.0×
Liquidity
Current ratio	15.1×-4.3×	12.6×-2.8×	11.3×-7.3×	11×-4.8×	19.5×-4.5×
Quick ratio	15.1×-4.3×	12.6×-2.8×	11.3×-7.3×	11×-4.8×	19.5×-4.5×
Cash ratio	3.4×0.0×	3×+0.9×	3.3×-1.5×	2.2×-0.7×	3.4×-0.1×
Leverage
Debt-to-equity	0.1×0.0×	0.1×0.0×	0×0.0×	0×0.0×	0×0.0×
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Interest coverage	-49.3×+104×	-74.1×+60.0×	-153.3×-19.3×	-176.1×-61.3×	-153.7×-18.0×
Valuation
Market capitalization	$2B+82.0%	$2.97B+95.6%	$1.76B+1.4%	$1.2B+44.1%	$1.1B-0.1%
Enterprise value	$1.86B+85.0%	$2.79B+96.6%	$1.62B+3.6%	$1.1B+47.9%	$1.01B-2.3%
Price / sales	28.2×-3,609×	41.9×-4,986×	24.9×-5,727×	3,921.8×+1,039×	3,637.1×-179×
Price / book	3.1×+1.3×	4.1×+1.9×	3.5×+1.0×	2.3×+0.8×	1.8×-0.1×
EV / sales	26.2×-3,303×	39.4×-4,667×	22.8×-5,143×	3,612.8×+1,025×	3,328.8×-245×
Free cash flow yield	-15.2%+10.3pp	-9.3%+6.0pp	-18.5%-7.2pp	-25.9%-5.6pp	-25.5%-10.2pp
Earnings yield	-18%+10.0pp	-11.5%+6.2pp	-17.1%-2.3pp	-28.8%-1.3pp	-28.1%-8.2pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Viridian Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Viridian Therapeutics, Inc.'s profit margins?: Viridian Therapeutics, Inc. (VRDN) runs a 36.3% gross margin and a -543.9% operating margin, with a -508.5% net margin.
Where do Viridian Therapeutics, Inc.'s ratios come from?: Every ratio is computed from Viridian Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.